KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD)

Year	Entry
2006	Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz K-G, Young EW, Pisoni RL. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. October 2006;70(7):1358-1366.
2000	Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. November 2000;27(5):687-694.
1999	Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR; Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. August 18, 1999;282(7):637-645.
2003	Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. November 2003;18(11):1932-1941.
1996	Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. February 1996;18(2):75-85.
2001	Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermittently administered human parathyroid hormone(1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. January 2001;16(1):157-165.
2001	Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E. Risk of new vertebral fracture in the year following a fracture. JAMA. January 17, 2001;285(6):320-323.
1998	Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. May 15, 1998;128(10):793-800.
2006	Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. June 1, 2006;69(11):1945-1953.
2001	Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. NEJM. May 10, 2001;344(19):1434-1441.
1999	Currey JD. The design of mineralised hard tissues for their mechanical functions. J Exp Biol. December 1999;202(23):3285-3294.
2000	Kanis JA, Glüer C-C; Committee of Scientific Advisors, International Osteoporosis Foundation. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int. March 2000;11(3):192-202.
2000	Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. July 2000;58(1):396-399.
2008	Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. NEJM. March 20, 2008;358(12):1304-1306.
2000	Garner P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. August 2000;15(8):1526-1536.
2000	Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. April 2000;15(4):721-739.
2003	Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. NEJM. September 25, 2003;349(13):1207-1215.
2006	Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA. December 27, 2006;296(24):2927-2938.
2008	Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int. April 2008;19(4):385-397.
2005	Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N. Assessment of fracture risk. Osteoporos Int. June 2005;16(6):581-589.
2007	Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg M-A, La Croix A, McCloskey E, Mellstrom D, Melton LJ, Pols H, Reeve J, Sanders K, Schott A-M, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. August 2007;18(8):1033-1046.
2002	Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SAA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. July 17, 2002;288(3):321-333.
2008	Keaveny TM, Bouxsein ML. Theoretical implications of the biomechanical fracture threshold. J Bone Miner Res. October 2008;23(10):1541-1547.
2005	Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ III, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A. Predictive value of BMD for hip and other fractures. J Bone Miner Res. July 2005;20(7):1185-1194.

Year	Entry
2020	Desbiens L-C, Goupil R, Mac-Way F. Predictive value of quantitative ultrasound parameters in individuals with chronic kidney disease: a population-based analysis of CARTaGENE. Bone. January 2020;130:115120.
2020	Iseri K, Qureshi AR, Dai L, Ripsweden J, Heimbürger O, Baranya P, Bergström I, Stenvinkel P, Brismar TB, Lindholm B. Bone mineral density at different sites and 5 years mortality in end-stage renal disease patients: a cohort study. Bone. January 2020;130:115075.
2020	Przedlacki J, Buczyńska-Chyl J, Koźmiński P, Niemczyk E, Wojtaszek E, Gieglis E, Żebrowski P, Podgórzak A, Wściślak J, Wieliczko M, Grochowski J, Kędzierska M, Kaczanowska B, Wyszyńska A, Sitkowska-Kurzec Z, Klatko W, Gellert R, Daniewska D, Osuch D, Stryjewski D, Świtalski M, Piotrowski A, Stopiński M, Kędzierski P, Rydzewski A, Fiderkiewicz B, Wypych-Birecka M, Śliwicka D, Durlik M, Grzeszczyk M, Sokalski A, Papliński M, Hartman J, Imiela J, Małecki R, Bolesta A, Niemczyk S, Klimm W, Wierzbicki P, Gorczyńska J, Piórecki M, Gołębiewski S, Horbacz R, Małyszko J, Matuszkiewicz-Rowińska J. FRAX prognostic and intervention thresholds in the management of major bone fractures in hemodialysis patients: a two-year prospective multicenter cohort study. Bone. April 2020;133:115188.
2020	Aaltonen L, Koivuviita N, Seppänen M, Tong X, Kröger H, Löyttyniemi E, Metsärinne K. Correlation between ¹⁸F-Sodium Fluoride positron emission tomography and bone histomorphometry in dialysis patients. Bone. May 2020;134:115267.
2021	Salam S, Gallagher O, Gossiel F, Paggiosi M, Eastell R, Khwaja A. Vascular calcification relationship to vascular biomarkers and bone metabolism in advanced chronic kidney disease. Bone. February 2021;143:115699.
2021	Lalayiannis AD, Fewtrell M, Biassoni L, Silva S, Goodman N, Shroff R, Crabtree NJ. Studying bone mineral density in young people: the complexity of choosing a pQCT reference database. Bone. February 2021;143:115713.
2020	Fujita R, Ota M, Sato D, Nakazawa D, Kimura-Suda H, Nakamura F, Shimizu T, Kobayashi H, Iwasaki N, Takahata M. Comparison of the efficacy and renal safety of bisphosphonate between low-dose/high-frequency and high-dose/low-frequency regimens in a late-stage chronic kidney disease rat model. Calcif Tiss Int. October 2020;107(4):389-402.
2021	Bacchetta J, Bernardor J, Garnier C, Naud C, Ranchin B. Hyperphosphatemia and chronic kidney disease: a major daily concern both in adults and in children. Calcif Tiss Int. January 2021;108(1):116-127.
2021	Cannata-Andía J, Carrillo-López N, Ferreira A. Bone in CKD, a fascinating evolving topic. Calcif Tiss Int. April 2021;108(4):407-409.
2021	Cannata-Andía JB, Martín-Carro B, Martín-Vírgala J, Rodríguez-Carrio J, Bande-Fernández JJ, Alonso-Montes C, Carrillo-López N. Chronic kidney disease—mineral and bone disorders: pathogenesis and management. Calcif Tiss Int. April 2021;108(4):410-422.
2021	Santos F, Díaz-Anadón L, Ordóñez FA, Haffner D. Bone disease in CKD in children. Calcif Tiss Int. April 2021;108(4):423-438.
2021	Komaba H, Ketteler M, Cunningham J, Fukagawa M. Old and new drugs for the management of bone disorders in CKD. Calcif Tiss Int. April 2021;108(4):486-495.
2021	Ferreira AC, Cohen-Solal M, D’Haese PC, Ferreira A; European Renal Osteodystrophy (EUROD), an initiative of the CKD-MBD working group of the ERA-EDTA. The role of bone biopsy in the management of CKD-MBD. Calcif Tiss Int. April 2021;108(4):528-538.
2021	Pimentel A, Ureña-Torres P, Bover J, Fernandez-Martín JL, Cohen-Solal M. Bone fragility fractures in CKD patients. Calcif Tiss Int. April 2021;108(4):539-550.
2016	Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis — 2016. Endocr Pract. September 1, 2016;22(suppl 4):1-42.
2020	Alarkawi D, Ali MS, Bliuc D, Pallares N, Tebe C, Elhussein L, Caskey FJ, Arden NK, Ben‐Shlomo Y, Abrahamsen B, Diez‐Perez A, Pascual J, Pérez‐Sáez MJ, Center JR, Judge A, Cooper C, Javaid MK, Prieto‐Alhambra D. Oral bisphosphonate use and all‐cause mortality in patients with moderate–severe (grade 3B‐5D) chronic kidney disease: a population‐based cohort study. J Bone Miner Res. May 2020;35(5):894-900.
2021	Fusaro M, Cozzolino M, Plebani M, Iervasi G, Ketteler M, Gallieni M, Aghi A, Locatelli F, Cunningham J, Salam S, Zaninotto M, Ravera M, Russo D, Mereu MC, Giannini S, Brandi ML, Ferrari S, Sella S, Egan CG, Bellasi A, Lullo LD, Tripepi G, Nickolas T. Sevelamer use, vitamin K levels, vascular calcifications, and vertebral fractures in hemodialysis patients: results from the VIKI study. J Bone Miner Res. March 2021;36(3):500-509.
2021	Khairallah P, Nickolas TL. Bisphosphonates in kidney disease: safety first. J Bone Miner Res. May 2021;36(5):817-819.
2020	Malmgren L, McGuigan FE, Christensson A, Akesson KE. Kidney function and its association to imminent, short- and long-term fracture risk: a longitudinal study in older women. Osteoporos Int. January 2020;31(1):97-107.
2020	Chao C-T, Wang J, Huang J-W, Chan D-C, Hung K-Y, Chien K-L; COhort of GEriatric Nephrology in NTUH (COGENT) study group. Chronic kidney disease–related osteoporosis is associated with incident frailty among patients with diabetic kidney disease: a propensity score–matched cohort study. Osteoporos Int. April 2020;31(4):699-708.
2020	Kwon YE, Choi HY, Oh HJ, Ahn SY, Ryu D-R, Kwon YJ. Vertebral fracture is associated with myocardial infarction in incident hemodialysis patients: a Korean nationwide population-based study. Osteoporos Int. October 2020;31(10):1965-1973.